 |
|
1-888-632-5353
M-F 8 AM - 9 PM EST
|
|
is Searching for
Plans in ZIP Code
|
Sorry, that ZIP code
was not found.
Try Again
|
|
|
is Searching for
Dentist in ZIP Code
|
|
|
|
you are here: DentalPlans.com > Dental Health Articles > Research > Weill Cornell Team Discovers Molecular "Missing Link" Driving Nerve Cell Regrowth
| |
|
|
|
Updated: 11/16/2006 4:33:57 PM |
|
|
An enzyme called sAC helps spur the growth of nerve endings in the developing embryo, and might also be used to someday regrow these "axons" in adults paralyzed by spinal cord injury.
The discovery, by a team of researchers at Weill Cornell Medical College in New York City, is reported in last month's issue of Nature Neuroscience.
"Identifying soluble adenylyl cyclase (sAC) as a key player in axonal growth has been like finding a crucial 'missing link' in the biochemical chain that leads to nerve cell regeneration," explains study senior author Dr. Samie Jaffrey, associate professor of pharmacology at Weill Cornell Medical College.
"With this new piece of the puzzle, we can begin serious work on introducing sAC directly into damaged spinal cords, where we hope it will encourage axons to seek out vital new connections. The ultimate goal is a treatment that can prevent paralysis or restore movement to paralyzed individuals," he says.
The discovery may also have implications for the treatment of other conditions characterized by impaired axonal growth, such as certain developmental disorders and diabetes-linked damage to peripheral nerves.
sAC has had a long association with Weill Cornell ever since two of the Medical College's noted pharmacology researchers, Drs. Jochen Buck and Lonny Levin, first identified the enzyme 8 years ago. These two investigators (both of whom are listed as co-authors on the current paper) also discovered that high levels of sAC are essential to the activation of another biochemical growth "switch" called cyclic AMP (cAMP).
"cAMP turns axonal growth on or off," explains study lead author Karen Y. Wu, a graduate student in the Department of Pharmacology at Weill Cornell. "During embryonic and fetal development, there's a lot of cAMP around. That pushes new nerves to grow, reach out and make necessary connections."
However, adult nerve cells -- which typically lack the ability to form new connections -- have only miniscule amounts of cAMP.
"We knew that high levels of cAMP helped spur axonal growth in developing cells. But what was the physiologic signal that triggered cAMP production? That was the real puzzle," Wu says. "We wondered if this new molecule, sAC, might be present and active around nerve growth cones -- the tiny 'buds' at the tip of the axon that direct its growth."
The experiments she and Dr. Jaffrey conducted found that it was.
Observing the development of nerve cells derived from embryonic rats, the researchers first determined that sAC was expressed in high amounts by developing rat axons.
They then used pharmacologic and genetic techniques to remove sAC from around the axons' growth cones.
"When we took sAC away, the axons suddenly failed to grow," says Dr. Jaffrey. "In fact, without sAC, these embryonic axons began to resemble axons in injured adult spinal cords -- axons that were incapable of growth."
Reversing the experiment, they used similar techniques to overexpress sAC, flooding nerve growth cones with the enzyme.
"The result: accelerated axonal growth," according to Wu.
The discovery fills in a crucial step in the biochemical "chain of command" that fosters axonal growth, the researchers say.
Here's how they believe it works:
First, proteins that promote axonal outgrowth, such as a signaling molecule called netrin-1, boost levels of calcium around the growth cone. This sudden rise in calcium is the "go" signal for sAC, which triggers the production of cAMP. High levels of cAMP are a signal to axons that growth can begin.
"Now that we know the major steps involved in this process, we hope to replicate it using gene therapy approaches at the site of spinal cord injury," explains Dr. Jaffrey.
His team's next step: introducing sAC to adult axons via a harmless virus that is genetically designed to home in on nerve growth cones. The virus would then express sAC in large quantities at the site.
"Hopefully, you'd get a physiologically relevant boost in cAMP, in the same way that developing axons normally experience it in the embryo," Wu says. "The result, we hope, would be axonal regrowth and some restoration of nerve function and movement."
These laboratory experiments could begin in the relatively near future, she says.
The ultimate goal is an injected therapy that might help patients with spinal cord injury avoid paralysis, or help those already paralyzed regain function.
"I really think that there will someday be gene therapy along these lines, with agents like sAC introduced to the site of injury to spur regeneration. This would be especially useful in that really critical period right after an accident," Dr. Jaffrey says.
The findings also deepen our understanding of healthy and unhealthy neuronal development, the researchers say.
"For example, certain fetal and childhood developmental disorders are closely associated with impaired axonal growth," Dr. Jaffrey says. "While we're a long way off from effective prevention or treatment for many of these disorders, this new discovery points the way to important new avenues of research."
This work was funded by grants from the U.S. National Institutes of Health, the Christopher Reeve Paralysis Foundation, the Barbara and Stephen Friedman Fellowship Endowment, the American Diabetes Association, the Hirschl Weill-Caulier Trust, and the Ellison Medical Foundation.
|
|
|
|
|
|
|
|
The materials and articles published on DentalPlans.com are for informational purposes only. Although DentalPlans.com strives to be accurate and complete, the information is provided without liability for errors. DentalPlans.com does not warrant the accuracy or completeness of the information, text graphics, links, or other items contained on DentalPlans.com.
DentalPlans.com expressly disclaims liability for errors or omissions in these materials and DentalPlans.com makes no commitment to update the information on DentalPlans.com.
DentalPlans.com expressly disclaims all liability for the use or interpretation by others of information on DentalPlans.com. Decisions based on information contained on DentalPlans.com are the sole responsibility of the visitors, and visitors agree to hold DentalPlans.com and its Affiliates harmless against any claims for damages arising from decisions visitors make on such information.
Nothing on DentalPlans.com constitutes medical advice or other forms of advice. DentalPlans.com assumes no responsibility for material created or published by third parties linked to DentalPlans.com with or without DentalPlans.coms knowledge.
|
|
| |
|
Terms of Use | Privacy Policy | Site Map | Newsletter | Info to Go |
DP Goes Green |
Affiliate Program | Contact Us
|
The DENTALPLANS.COM website is administered by DENTALPLANS.COM, INC., a licensed Florida Discount Medical Plan Organization, 8100 S.W. 10th Street Suite #2000, Plantation, FL 33324. Plans and Programs offered by DentalPlans.com are not health insurance policies. Plans and Programs offered by DentalPlans.com provide discounts at certain health care providers for medical services. Plans and Programs offered by DentalPlans.com do not make payments directly to the providers of medical services. The Plan or Program member is obligated to pay for all health care services but will receive a discount from those health care providers who have contracted with the Plan, Program or discount plan organization.
© 1999-2009 DentalPlans.com, Inc. All Rights Reserved. Patents Pending. |
   |
|
| |
|  |
|